Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $49.00 Consensus Price Target from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $49.00.

A number of equities analysts have recently weighed in on the company. B. Riley increased their price target on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. Morgan Stanley increased their target price on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 14th. Leerink Partners reissued an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research report on Monday, August 26th. Finally, Oppenheimer lifted their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $46.41 on Tuesday. The company’s 50-day moving average is $46.45 and its two-hundred day moving average is $39.87. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $53.27. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of -18.49 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The business’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.67) EPS. As a group, equities analysts anticipate that Kymera Therapeutics will post -2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after buying an additional 996,300 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Artal Group S.A. lifted its stake in Kymera Therapeutics by 19.6% during the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after purchasing an additional 496,400 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Kymera Therapeutics by 229.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock worth $17,177,000 after purchasing an additional 469,947 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Kymera Therapeutics in the first quarter valued at approximately $17,122,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.